Hepatitis B Carriers: How Should Liver Cancer Surveillance Work? (2026 Guide)

If you carry hepatitis B or have cirrhosis, the standard national screening approach is a liver ultrasound plus blood tests (including tumor markers) every 6 months, and the guiding principle is that antiviral therapy should never be paused — it continues for life.

Key Takeaways

• Hepatitis B carriers and cirrhosis patients undergo national screening at 6-month intervals with ultrasound and blood tests, and this approach is a major reason Korea has a relatively high rate of detecting liver cancer at small sizes.
• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registry Statistics, 2019–2023), and this figure reflects nationwide statistics, not any single institution's outcomes.
• For comparison, the US SEER data for 2016–2022 shows a 5-year relative survival rate of 21.9% for liver and intrahepatic bile duct cancer.
• Because liver cancer usually develops on top of chronic hepatitis or cirrhosis, treatment decisions depend not only on tumor stage but also on liver function grade (Child-Pugh) and portal pressure.
• As a rule, hepatitis B antiviral medication should be continued without interruption regardless of whether liver cancer is diagnosed or being treated.

Why Do Hepatitis B Carriers Need Separate Liver Cancer Screening?

• Because liver cancer nearly always arises against a backdrop of chronic hepatitis or cirrhosis, people with these underlying conditions need closer monitoring than the general population.
• Korea operates a national screening system requiring hepatitis B carriers and cirrhosis patients to undergo ultrasound and blood tests every 6 months. This interval is a key reason tumors are detected at relatively small sizes.
• Unlike many other cancers, liver cancer can often be diagnosed without a biopsy when contrast-enhanced CT or MRI shows a characteristic blood-flow pattern (strong enhancement in the arterial phase followed by washout), combined with tumor markers such as AFP.

What Does Screening Check? — Step-by-Step

1. Step 1: A liver ultrasound every 6 months to check for new nodules or tumors.
2. Step 2: Blood tests for tumor markers such as AFP and PIVKA-II, along with liver function indicators including bilirubin, albumin, coagulation (INR), and platelet count.
3. Step 3: If the ultrasound or markers show abnormalities, contrast-enhanced CT or MRI is used to examine the blood-flow pattern and narrow down the diagnosis.
4. Step 4: If imaging results are ambiguous or metastasis from another cancer is suspected, a biopsy is added.
5. Step 5: Once diagnosis is confirmed, treatment direction (using staging systems such as BCLC) is determined by considering the number, size, and vascular invasion of tumors together with Child-Pugh grade and overall health status.

Should Antiviral Medication Be Continued?

• Yes — continuation is the principle. Hepatitis B antiviral medication should not be stopped before or after liver cancer treatment, since it also relates to preserving liver function and keeping more treatment options open going forward.
• Regardless of cancer stage, the state of chronic hepatitis control determines the range of treatments that remain viable, so antiviral therapy and liver function tests are lifelong management items independent of whether liver cancer develops.
• As a general principle of post-treatment follow-up, the typical pattern for the first 1–2 years is repeated contrast-enhanced CT or MRI and AFP testing every few months, with intervals gradually lengthening afterward — though the actual schedule is set by the treating medical team based on the individual's condition.

FAQ — Can Liver Cancer Be Diagnosed Without a Biopsy?

Often, yes. Liver cancer is frequently diagnosed by combining imaging findings (the characteristic blood-flow pattern on contrast-enhanced CT or MRI), tumor markers such as AFP, and hepatitis status, meaning a review can be completed without a biopsy. A biopsy is only added when imaging is ambiguous or metastasis from another cancer is suspected.

FAQ — Which Hospital's Outcomes Are These Numbers Compared Against?

The survival rates and screening-related figures mentioned here are not the outcomes of any specific hospital but nationwide statistics from the National Cancer Registry Statistics (2019–2023) and SEER. Individual outcomes can vary depending on stage, liver function grade, and hepatitis control status, and these figures should not be taken as predictions for any one person.

Sources and Notes

• This article was prepared based on the National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea, Central Cancer Registry), SEER 2016–2022, and National Cancer Information Center guidance on post-treatment follow-up testing.
• This content is intended for general medical information purposes only; actual diagnosis, treatment methods, and outcomes may vary by individual condition. Please consult with your medical team to determine an accurate diagnosis and treatment plan.